Zenyaku Kogyo

Privately held: no public share price · Japan

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
4Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Rituximab(Rituxan)
Approved
CD20 · CD20-directed Cytolytic AntibodyMonoclonal antibody
Rheumatoid ArthritisDiffuse Large B-Cell LymphomaFollicular LymphomaChronic Lymphocytic Leukemia

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Est. primary completion 2026-12-01 · NCT03758989 · CT.gov ↗
What to watch
2027 (2)
July 2027 (1)
Rituximab · RituxanPhase 2DLBCL, Lymphoma, B-Cell
Est. primary completion 2027-07-31 · NCT04594798 · CT.gov ↗
What to watch
October 2027 (1)
Rituximab · RituxanPhase 3Large B-Cell Lymphoma
Est. primary completion 2027-10-01 · NCT06047080 · CT.gov ↗
What to watch
2029 (1)
November 2029 (1)
Rituximab · RituxanPhase 1/2Mature B-Cell Non-Hodgkin Lymphoma
Est. primary completion 2029-11-30 · NCT05533775 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.